Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study

Objective: To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods: Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time(ACT), clot rate(CR) and platelet function(PF) by Sonoclot coagulation and platelet function analyzer instrument. Results: For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear(or log linear) relationship between ACT, CR, PF value and drug concentration(P0.01). Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride(P0.01). Under the same ACT values, the puerarin corresponding CR values(CR = e~(-0.0062) ACT+4.31, P2.2 e~(-16)) were always higher than the corresponding values(CR = e-~(0.0028) ACT+2.79, P-value2.2 e~(-16)) of heparin sodium. For high concentrations of puerarin(e.g. 3.8 mg/600 μL) and tirofiban hydrochloride(e.g. 0.8 μg/600 μL), PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions: Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.     

Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study

Objective: To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods: Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT), clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument. Results: For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT, CR, PF value and drug concentration (P<0.01). Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride (P<0.01). Under the same ACT values, the puerarin corresponding CR values (CR = e-0.0062ACT+4.31, P<2.2e-16) were always higher than the corresponding values (CR = e-0.0028ACT+2.79, P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL), PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions: Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.     

Endogenous Ouabain in Hypertensive Disorder Complicating Pregnancy

Expression of endogenous ouabain in placenta and the concentrations of serum ET-1 and NO were examined in 30 patients with hypertensive disorder complicating pregnancy (HDCP) and 30 healthy pregnant women to investigate the effect of endogenous ouabain on HDCP. Compared with the healthy pregnant group, the expression of endogenous ouabain dramatically increased in the HDCP groups (P<0.01). There was a significantly positive correlation between the expression of en- dogenous ouabain with ET-1 (r= 0.5567, P<0.01), while the correlation of endogenous ouabain and NO was significantly negative (r=-0.6895, P<0.01). As expected, the correlation between ET-1 and NO was negative (r=-0.7796, P<0.01). ET-1 concentrations of maternal and cord sera in HDCP groups were significantly higher in comparison with healthy pregnant group (P<0.01). On the con- trast, NO concentrations were much lower in the maternal and cord sera of HDCP groups as com- pared with healthy pregnant group (P<0.01). Our data suggest that endogenous ouabain is directly involved in the nosogenesis of HDCP, with accompanying decreased NO and the elevated of ET-1.     

Fribrinolysis Kinetics and Its Application

A new, convenient, and rapid method for kinetic measurement of human fibrinolysis was established. The alteration of absorbance (A) in the process of blood coagulation and lyses was auto-matically scanned and recorded using a UV2000 spectrophotometer connected to a computer. The parameters of human fibrinolysis kinetics were established. Urokinase at 20 U/mL was the optimal concentration used. There was significant difference in fibrinolysis kinetics and plasma plasminogen concentration between 22 normal subjects and 27 patients with acute myeloblastic leukemia (P<0.05 and <0.01 respectively). The coefficience of variation was (5.24±1.51)%. This method could also be used to measure the plasma fibrinogen concentration at the same time. It was concluded that this method was stable and was capable of providing dynamic, direct experimental data and multipareme-ters for clinicians. It was also valuable in evaluating the anti- and pro-fibrinolytic capcity of patients' plasmas, allowing for monitoring of therapy, choice of drugs and adjustment of drug concentrations.     

Antitumor Effect of Interferon-α on U937 Human Acute Leukemia Cells in vitro and Its Molecular Mechanism

In order to investigate the antitumor effect and molecular mechanism of interferon-α(IFN-α) on human acute myeloid leukemia cell line U937 cells in vitro,the proliferation of U937 cells was determined by MTT assay,the apoptosis rate was analyzed by flow cytometry(FCM),and the mRNA expression of cell cycle regulatory protein cyclin E was detected by RT-PCR.The results showed that IFN-α could inhibit the proliferation of U937 cells significantly in a dose-and time-dependent way(P<0.01),and induce the apoptosis of U937 cells also in a dose-and time-dependent manner at the concentration of 1000-4000 U/L(P<0.01).The apoptosis rate of U937 cells was even over 50% when cultured with IFN-α for 36-48 h at the concentration of 2000-4000 U/L.Moreover,the expression of cyclin E mRNA was markedly inhibited by the addition of IFN-α,and the inhibition was time-dependent(P<0.01).It was concluded that the anti-leukemia mechanism of IFN-α might be correlated with its antiproliferative and apoptotic inducing effects,and the down-regulation of the cyclin E expression might be one of its molecular mechanisms.     

ROLE OF B LYMPHOCYTE AND ITS SUBPOPULATIONS IN PATHOGENESIS OF IMMUNORELATED PANCYTOPENIA

Objective To measure the quantities and apoptosis-related protein levels of B lymphocyte in the patients with immunorelated pancytopenia(IRP)and explore the action of B lymphocyte in the pathogenic mechanism of IRP. Methods Quantities of whole B lymphocytes and CD5 B lymphocytes as well as the expressions of Fas and Bcl-2 in B lymphocytes in 35 patients with untreated IRP, 15 IRP patients in complete remission (CR), and 10 normal controls were assayed by flow cytometry. Results The percentages of B lymphocyte and CD5 B lymphocyte were significantly higher in untreated IRP patients than in CR IRP patients and normal controls (P<0.05), and there was no significant difference between the latter two groups (P>0.05). There was no significant difference of Fas expression in B lymphocyte among three groups (P>0.05). The expression of Bcl-2 in B lymphocyte was significantly higher in untreated patients than in CR patients or normal controls (P<0.01), and significantly higher in CR patients than in normal controls (P<0.01). The apoptosis-related index was significantly lower in untreated patients than in CR patients or normal controls (P<0.05), and significantly lower in CR patients than in normal controls (P<0.05). The percentage of B lymphocyte was positively correlated with post-treated response time(r=0.53, P<0.01). Conclusion The production of auto-antibodies in IRP patients probably has some relationship with the abnormal quantities of B lymphocyte and its subpopulations as well as with the inhibition of B lymphocyte apoptosis.     

In vitro anticoagulation monitoring of low-molecular-weight heparin

Background Although low-molecular-weight heparin has replaced unfractionated heparin to become the primary anticoagulation drug for treatment of acute coronary syndrome, there is no convenient bedside monitoring method. We explored the best laboratory monitoring method of low-molecular-weight heparins （enoxaparin, dalteparin, and nadroparin） by use of the Sonoclot coagulation analyzer to monitor the activated clotting time.
Methods A total of 20 healthy volunteers were selected and 15 ml of fasting venous blood samples were collected and incubated. Four coagulants, kaolin, diatomite, glass bead, and magnetic stick, were used to determine the activated clotting time of the low-molecular-weight heparins at different in vitro anti-Xa factor concentrations. A correlation analysis was made to obtain the regression equation. The activated clotting time of the different low-molecular-weight heparins with the same anti-Xa factor concentration was monitored when the coagulant glass beads were applied.
Results The activated clotting time measured using the glass beads, diatomite, kaolin, and magnetic stick showed a linear correlation with the concentration of nadroparin （r = 0.964, 0.966, 0.970, and 0.947, respectively）. The regression equation showed that the linear slopes of different coagulants were significantly different （glass beads 230.03 s/IU, diatomite 89.91 s/IU, kaolin 50.87 s/IU, magnetic stick could not be calculated）. When the concentration of the anti-Xa factor was the same for different low-molecular-weight heparins, the measured activated clotting time was different after the application of the glass bead coagulant.
Conclusions The glass bead coagulant is most feasible for monitoring the in vitro anticoagulation activity of nadroparin The different effects of different low-molecular-weight heparins on the activated clotting time may be related to the different anti-11a activities.     

Effect of Jinmaitong (筋脉通) serum on the proliferation of rat Schwann cells cultured in high glucose medium

Objective:To investigate the effect of Jinmaitong(筋脉通,JMT)serum on the proliferation of rat Schwann cells(SCs)primarily cultured in high glucose medium.Method:SOs were primarily cultured in Dulbecco's minmum essential medium(DMEM control),50 mmol/L glucose medium(50 mmol/L Glu),75 mmol/L glucose medium(75 mmol/L Glu),as well as 50 mmol/L glucose medium,with different concentrations of JMT serum(undiluted,1:2 diluted and 1:8 diluted)and Neurotropin(Ntp), respectively.The proliferation of SCs under different conditions was detected by MTT.Result:SCs grew exuberantly in DMEM within 24-72 h,but slowed down at 96 h.The proliferation of SCs was inhibited in 50 mmol/L Glu and 75 mmol/L Glu after cultures of 48,72 and 96 h,which showed that both were significantly different compared to the control group(P<0.01).The inhibition was more significant in 75 mmol/L Glu than in 50 mmol/L Glu(P<0.05).Spearman's rho analysis revealed that the proliferation of SCs had a negative correlation with the concentration of glucose(r=-0.471,P<0.01).Excluding the time factor,partial correlation showed similar results(r=-0.679,P<0.01).After 48 h,the proliferation of SCs increased significantly in JMT1:2 and Ntp compared with 50 mmol/L Glu(control 0.437±0.019,50 mmol/ L Glu 0.367±0.035,JMT1:2 0.426±0.024,Ntp 0.422±0.013;P<0.01),and there were no statistically significant differences among the JMT groups,the Ntp group and the control group(P>0.05).Conclusions: The proliferation of SCs was inhibited in high glucose medium,and the inhibition was reduced by different concentrations of JMT serum,especially at JMT1:2.     

The influence of insulin on secretion of IGF-Ⅰ and IGFBP-Ⅰ in cultures of human endometrial stromal cells

Objectives To study the influence of insulin on IGF-Ⅰ and IGFBP-Ⅰ secretion of the human endometrial stromal cells. Methods Late proliferative phase endometrial stromal cells were isolated from endometrium tissues and then cultured for 24 h in Hams F-12 only as a control and in Hams F-12 with different concentrations of estradiol (E2) and insulin (INS) as treated groups. Simultaneously, the endometrial stromal cells from late secretory phase endometrium were cultured for 24 h in Hams F-12 only as a control and in Hams F-12 supplemented with different concentrations of progesterone (P) and insulin as treated groups. After 24 h of culturing, the mediums were collected for either IGF-Ⅰ or IGFBP-Ⅰ assays. Result The concentrations of IGF-Ⅰ in medium from cultured endometrial stromal cells in the proliferative phase were 0.78±0.47 ng/ml in the hormone-free control group; 1.44±0.59 ng/ml and 1.39± 0.33 ng/ml in 100 pg/ml E2 group and 20 μU/ml INS group, which was higher than that of the control group (P&lt;0.05 and P&lt;0.01, respectively). The IGF-Ⅰ concentration in the 100 μU/ml INS group was 2.03±0.53 ng/ml, which was higher than that of the 20 μU/ml INS group (P&lt;0.01). Levels of IGF-Ⅰ in the 100 pg/ml E2 plus 20 μU/ml INS group was 2.18±0.36 ng/ml, which was significantly higher than that of the 20 μU/ml INS and 100 pg/ml E2 group (P&lt;0.01), but lower than that of the 100 pg/ml E2 plus 100 μU/ml INS group (3.42±0.75 ng/ml), P&lt;0.01. The concentration of IGFBP-Ⅰ in medium from cultured endometrial stromal cells in the secretory phase was 2.50±1.39 ng/ml in the hormone-free control group and 5.44±2.09 ng/ml in the 10 pg/ml P group, which was significantly higher than that of the control (P&lt;0.01). IGFBP-Ⅰ concentration in 20 μU/ml INS group was 0.16±0.58 ng/ml, which was lower compared with control, but higher compared with the 100 μU/ml INS group (P&lt;0.01). The level of IGFBP-Ⅰ in the 10 ng/ml P plus 20 μU/ml INS group was 2.10±1.17 ng/ml, lower compared with the 10 ng/ml P group, but higher compared with the 10 pg/ml P plus 100 μU/ml INS group, P&lt;0.01. Conclusions Insulin can stimulate basal (without hormone) and E2-stimulated IGF-Ⅰ secretion in cultured stromal cells from human late proliferative endometrium in a dose-dependent manner. Insulin can suppress basal (without hormone) and P-stimulated IGFBP-Ⅰ secretions in cultured stromal cells from human secretory endometrium in a dose-dependent manner.     

导管室中应用达肝素时抗凝活性的监测

目的:本研究旨在探讨激活凝血时间(ACT)是否可作为达肝素在导管室中应用时有效的抗凝监测手段.方法:共入选108例患者,冠状动脉造影(CAG)术前5min一次静脉注射达肝素60IU/kg,术中不再追加抗凝药物.所有患者均在静脉注射达肝素后5min取血测量ACT.其中30例患者作为抗凝活性检测组分别在达肝素注射前和注射后6个时间点取血检测抗凝参数ACT、aPTT、抗Xa因子和抗Ⅱa因子活性,观察静脉注射达肝素后的时间-抗凝效应关系.结果:静脉注射达肝素后5minACT值由基线121s升高到193s,10min时达峰值208s,并持续120min无明显下降(P＜0.001).aPTT、血浆抗Xa和抗Ⅱa因子活性也呈类似趋势.结论:ACT和aPTT对静脉注射达肝素敏感.ACT可以用来监测PCI期间静脉注射达肝素的抗凝活性.     

体外循环采用高岭土激活全血凝固时间监测43例临床报告

目的:心脏手术体外循环,采用高岭土作为试剂激活全血凝固时间监测,以下简称ACT监测,极大的提高了体外循环转流的安全性。方法:本组对43例病人使用高岭土做为试剂,对体外循环转流前ACT基础值(即生理值),体外循环转流中和体外循环转流后病员ACT值进行监测。结果:对心脏手术体外循环前和转流中肝素用量,以及停机后中和肝素的鱼精蛋白用量提供了可靠的参考依据,保证与减少了体外循环手术中的凝血及手术后创面的出血与渗血。结论:心脏手术体外循环中用高岭土进行ACT监测,此方法经济、简单、便于操作、确保了心脏手术体外循环的安全进行。     

应用Sonoclot体外监测低分子肝素及磺达肝癸钠的抗凝作用

目的:探讨Sonoclot凝血仪在分析监测凝血与血小板功能的临床价值。方法:在gb试剂杯加入不同浓度的低分子肝素钠(0～1.6 IU/mL抗Xa因子)、低分子肝素钙(0～1.64 IU/mL抗Xa因子)、磺达肝癸钠(0～1.52μg/mL),抽取10例健康志愿者血样,并加入有药物的试剂杯中,用Sonoclot凝血仪进行检测,检测指标分别包括激活凝血时间(ACT)、凝血速率(CR)和血小板功能(PF)。结果:(1)3种抗凝药物随着浓度的增加,其ACT值逐渐增加,CR值逐渐下降,PF值逐渐下降。(2)对于同一治疗量的3种抗凝药物,低分子肝素钠(1.2 IU/mL抗Xa因子)与低分子肝素钙(1.23 IU/mL抗Xa因子),其ACT、CR、PF 3个参数的比较,P>0.05,无统计学差异。磺达肝癸钠(0.77μg/mL)与低分子肝素钠(1.2 IU/mL抗Xa因子)和低分子肝素钙(1.23 IU/mL抗Xa因子)相比,其ACT、CR、PF 3个参数均有差异性,均P<0.01。结论:Sonoclot凝血仪可以快速检测低分子肝素及磺达肝癸钠的抗凝效果以及对于血小板功能的影响,可以对临床给药剂量和个体化治疗做出指导。     

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis

Thromboembolic complications are a common and costly medical problem, associated with significant morbidity and mortality, especially in postoperative patients. There have been reports of death due to thromboembolic complications even after short procedures, e.g. arthroscopy. Low-molecular-weight heparins (LMWHs) (e.g., certoparin, dalteparin, enoxaparin, nadroparin, reviparin, tinzaparin) have been tested for treatment of deep vein thrombosis in comparison to unfractionated heparin (UFH) in many patients being effective and safe alternative for treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE). Fixed-dose subcutaneous LMWH once daily is in most cases of equivalent efficacy and safety compared to conventional UFH therapy. There may be less risk for bleeding, less platelet activation together with a control of markers of haemostatic system activation, and either no progression or regression of thrombus size in patients treated with LMWH. The handling of LMWH is more comfortable for patients and less time consuming for nurses and laboratories compared to UFH. The cost-effectiveness analysis showed that LMWH are more cost effective than UFH. It has been calculated that outpatient treatment with LMWH may save 1641 dollars per patient in comparison to hospital treatment. This economic benefit of outpatient treatment of DVT seems to be realized in different health systems. Women with antiphospholipid antibodies and a history of either prior thrombotic events or pregnancy loss are at high risk during pregnancy for either another fetal death or thrombosis and may benefit from treatment with LMWH. In patients with malignant tumors secondary prophylaxis or long-term treatment with LMWH is successful. Patients with a contraindication for oral anticoagulants may benefit from treatment with LMWH as do patients on chronic anticoagulation treatment scheduled for an operative intervention. In most instances LMWH (dalteparin, enoxaparin, nadroparin) treatment for DVT may be given once daily at a fixed dose without any harm, based on a prolonged antithrombin activity. Effectiveness and safety of LMWH (dalteparin, enoxaparin, nadroparin, tinzaparin) in comparison to UFH treatment on outpatient basis has been demonstrated in several studies. In summary, LMWHs have an established role in the treatment of DVT and pulmonary embolism (PE), on an in- and outpatient basis and could realize substantial savings. Most studies were performed with dalteparin, enoxaparin and nadroparin. There is evidence that LMWHs may help to prolong survival in cancer patients and to avoid complications of the acute coronary syndrome.     

Bio-Rad VariantII糖化血红蛋白分析仪改良试剂应用评价

目的对Bio-Rad VariantII糖化血红蛋白分析仪新试剂进行应用能力分析。方法对Bio-Rad VariantII糖化血红蛋白分析仪改良试剂的精密度、稀释线性分析、全血模式与稀释模式、标本稀释后的稳定性、与改良前试剂相关性等评价。结果批间精密度均≤1.4%,批内精密度均≤0.93%,全血模式精密度优于稀释模式。稀释线性理论值与实测值相关性良好（r=0.998 5,P〈0.01）。稀释与全血模式比较差异无统计学意义;而改良前试剂的两种模式差异有统计学意义（P〈0.01）,其稀释模式结果高于全血模式。稀释样本室温10h存放稳定,与0h差异无统计学意义（P〉0.05）。新试剂和改良前试剂有良好的相关性（全血r=0.994 2,P〈0.01;稀释r=0.995 2,P〈0.01）。新试剂和改良前试剂的全血模式测定结果差异无统计学意义（P〉0.05）,稀释模式结果则差异有统计学意义（P〈0.01）。结论 Bio-Rad VariantII糖化血红蛋白改良新试剂优于改良前,能更好地满足临床质量要求。     

奥扎格雷联合低分子肝素治疗急性脑梗死临床研究

目的:探讨奥扎格雷与低分子肝素联合治疗急性脑梗死的疗效和安全性.方法: 将145例急性脑梗死患者分成联合治疗组76例和对照组69例.观察治疗前后血小板计数,血小板聚集率、纤维蛋白原、高切应力、红细胞压积、凝血功能、影像学、卒中量表评分(NIHSS)及生活自理能力,并比较出血的发生率.结果:两组治疗后血小板聚集率(1min、最大聚集率)差异均有显著性(均P＜0.05),联合治疗组作用最明显(P＜0.05);联合治疗组血纤维蛋白原水平,血高切应力均降低(P<0.005,P<0.01).生活自理能力恢复联合治疗组(71.20%)优于对照组(18.12%).出血发生率2组之间比较差异无显著性(P＞0.05).3个月时2组NIHSS、MBI比较显示联合治疗组神经功能恢复明显优于对照组(均P＜0.001).结论:奥扎格雷联合低分子肝素治疗急性脑梗死有明显疗效,且安全性好.     

脑卒中后痉挛性偏瘫患者膝关节控制能力障碍的sEMG特征研究

目的 观察脑卒中后痉挛性偏瘫患者在屈伸患者膝关节时双侧大腿各肌群的表面肌电信号特征,为脑卒中痉挛性偏瘫患者膝关节运动控制障碍的康复训练提供电生理依据。 方法 使用表面肌电图(surface electromyography,sEMG)检测正常对照组35例健康人和2013年7月—2014年12月在浙江省台州医院住院的脑卒中后偏瘫下肢痉挛状态的35例患者股外侧肌、股内侧肌、股直肌及股二头肌的肌电信号变化,观察在膝关节屈曲和伸展状态下均方根值(RMS),协同拮抗率(CR)的变化对患者预后的影响。 结果 在膝关节伸展状态下时,健侧与患侧股外侧肌、股内侧肌、股直肌及股二头肌的RMS值显著小于正常对照组(P＜0.01),而健侧与患侧CR显著大于正常对照组(P＜0.05),但患侧的RMS值及CR均小于健侧(P＜0.05)。在膝关节屈曲状态下时,患侧股外侧肌、股内侧肌、股直肌及股二头肌的RMS值均小于正常对照组及健侧(P＜0.01);患侧股外侧肌、股内侧肌、股直肌及股二头肌CR大于正常对照组,但差异无统计学意义(P＞0.05);健侧股内侧肌及股二头肌的RMS值及CR均小于正常对照组,但差异无统计学意义(P＞0.05)。 结论 脑卒中后痉挛性偏瘫患者下肢健患侧屈伸肌都存在主动肌与拮抗肌协调性的异常,表面肌电图技术可以实时定量评价脑卒中后痉挛性偏瘫患者膝关节控制障碍主动肌与拮抗肌协调性,为制定康复方案及预后的评价提供有力的依据。      

用Sonoclot分析仪测评体外循环后凝血功能的改变

目的用Sonoclot凝血和血小板功能分析仪观察心脏直视手术体外循环前、后凝血功能的改变。方法选择20例体外循环下心脏手术患者，麻醉前及首次鱼精蛋白中和肝素后10min取静脉血用Sonoclot分析仪检测全血凝血和血小板功能，并进行激活全血凝固时间（ACT）测定。结果体外循环前后ACT差异无显著性（P=0．27），而使用玻璃珠作为促凝剂的检测试剂盒（gb—ACTKit）术后明显高于术前（P〈0．01），凝血速率（cR）术后明显降低（P=0．01），血小板功能（PF）降低但无显著差异（P=0．50）。结论Sonoclot分析仪能够早期检测体外循环后凝血功能的改变，是一种较为敏感的床边检测方法。